Edition:
United States

Sanofi SA (SASY.PA)

SASY.PA on Paris Stock Exchange

79.23EUR
11:38am EST
Change (% chg)

€1.00 (+1.28%)
Prev Close
€78.23
Open
€78.39
Day's High
€79.50
Day's Low
€78.27
Volume
3,059,629
Avg. Vol
2,460,494
52-wk High
€80.44
52-wk Low
€62.88

Chart for

About

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. Its segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality... (more)

Overall

Beta: 0.84
Market Cap(Mil.): €100,403.50
Shares Outstanding(Mil.): 1,251.76
Dividend: 3.03
Yield (%): 3.78

Financials

  SASY.PA Industry Sector
P/E (TTM): 25.03 28.12 29.34
EPS (TTM): 3.20 -- --
ROI: -- 14.10 13.58
ROE: -- 15.67 15.11

Berkshire invests in JPMorgan, Oracle as Buffett puts cash to work

Warren Buffett's Berkshire Hathaway Inc deepened its commitment to the U.S. financial industry, announcing a $4.02 billion stake in JPMorgan Chase & Co and new investments in PNC Financial Services Group Inc and Travelers Companies Inc, plus a stake in Oracle Corp.

Nov 14 2018

UPDATE 3-Berkshire invests in JPMorgan, Oracle as Buffett puts cash to work

Nov 14 Warren Buffett's Berkshire Hathaway Inc deepened its commitment to the U.S. financial industry, announcing a $4.02 billion stake in JPMorgan Chase & Co and new investments in PNC Financial Services Group Inc and Travelers Companies Inc, plus a stake in Oracle Corp .

Nov 14 2018

BRIEF-Sanofi: Analyses On Mortality From ODYSSEY OUTCOMES Trial Of Praluent

* ANNOUNCED ON SUNDAY ANALYSES ON MORTALITY FROM THE 18,924-PATIENT ODYSSEY OUTCOMES TRIAL

Nov 12 2018

Sanofi and Regeneron's Dupixent gets more positive feedback from U.S. FDA

PARIS The U.S. Food & Drug Administration (FDA) regulator has given more positive feedback on the Dupixent eczema treatment being developed by drugmakers Sanofi and Regeneron, the companies said on Tuesday.

Nov 06 2018

UPDATE 1-Sanofi and Regeneron's Dupixent gets more positive feedback from U.S. FDA

PARIS, Nov 6 The U.S. Food & Drug Administration (FDA) regulator has given more positive feedback on the Dupixent eczema treatment being developed by drugmakers Sanofi and Regeneron, the companies said on Tuesday.

Nov 06 2018

Sanofi and Regeneron's Dupixent gets more positive feedback from U.S. FDA - companies

PARIS, Nov 6 The U.S. Food & Drug Administration (FDA) regulator gave more positive feedback on the Dupixent eczema treatment being developed by drugmakers Sanofi and Regeneron, the companies said on Tuesday.

Nov 06 2018

Vaccines and Genzyme help Sanofi keep promise of return to growth

PARIS Sanofi lifted its 2018 profit target for the second time this year after robust sales of its vaccines and rare diseases division, Genzyme, helped it beat third-quarter profit expectations.

Oct 31 2018

UPDATE 2-Vaccines and Genzyme help Sanofi keep promise of return to growth

PARIS, Oct 31 Sanofi lifted its 2018 profit target for the second time this year after robust sales of its vaccines and rare diseases division, Genzyme, helped it beat third-quarter profit expectations.

Oct 31 2018

Vaccines and Genzyme help Sanofi keep promise of return to growth

PARIS, Oct 31 Sanofi narrowed its 2018 profit target for the second time this year after it posted higher-than-expected third-quarter profits, helped by robust sales growth at its key vaccines unit and its rare diseases Genzyme division.

Oct 31 2018

Sanofi drug Dupixent wins FDA approval to treat asthma

France's Sanofi SA said on Friday eczema drug Dupixent was approved by the U.S. Food and Drug Administration as an additional maintenance therapy in patients with two types of asthma.

Oct 19 2018

Earnings vs. Estimates